| pubmed-article:1715381 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0010453 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0229535 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0032016 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0037663 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0037657 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C1159339 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0074825 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0021665 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0021666 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:1715381 | lifeskim:mentions | umls-concept:C0063674 | lld:lifeskim |
| pubmed-article:1715381 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1715381 | pubmed:dateCreated | 1991-10-3 | lld:pubmed |
| pubmed-article:1715381 | pubmed:abstractText | The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF-I analogue, on the secretion of GH and IGF-binding protein (IGFBP) from cultured rat anterior pituitary cells were measured. IGF-I and des(1-3)IGF-I stimulated GH secretion at low concentrations (maximally effective at 1 and 0.1 micrograms/l respectively) and inhibited GH secretion at higher concentrations. The half-maximal inhibitory concentrations (IC50) were approximately 20 micrograms/l and 1 microgram/l for IGF-I and des(1-3)IGF-I respectively. Thus des(1-3)IGF-I was more potent than IGF-I in these effects on GH secretion. We postulate that the increased potency of des(1-3)IGF-I in affecting GH secretion is due to decreased binding of this peptide by pituitary IGFBP compared with IGF-I. In contrast with IGF-I and des(1-3)IGF-I, IGF-II did not stimulate GH secretion at low concentrations, but did inhibit GH secretion from pituitary cells with an IC50 of approximately 20 micrograms/l. Several IGFBPs ranging in molecular mass from 22,000 to 52,000 were detected in medium conditioned by cultured anterior pituitary cells. When measured by Western-ligand blotting and competitive ligand-binding techniques, these IGFBPs exhibited decreased binding of des(1-3)IGF-I compared with IGF-I and IGF-II. The production of IGFBP by anterior pituitary cells was stimulated by the addition of IGFs to the culture medium. | lld:pubmed |
| pubmed-article:1715381 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1715381 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1715381 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1715381 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1715381 | pubmed:issn | 0022-0795 | lld:pubmed |
| pubmed-article:1715381 | pubmed:author | pubmed-author:WallaceJ CJC | lld:pubmed |
| pubmed-article:1715381 | pubmed:author | pubmed-author:SilerK FKF | lld:pubmed |
| pubmed-article:1715381 | pubmed:author | pubmed-author:WaltonP EPE | lld:pubmed |
| pubmed-article:1715381 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1715381 | pubmed:volume | 130 | lld:pubmed |
| pubmed-article:1715381 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1715381 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1715381 | pubmed:pagination | 93-9 | lld:pubmed |
| pubmed-article:1715381 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:meshHeading | pubmed-meshheading:1715381-... | lld:pubmed |
| pubmed-article:1715381 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1715381 | pubmed:articleTitle | The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells. | lld:pubmed |
| pubmed-article:1715381 | pubmed:affiliation | Department of Biochemistry, University of Adelaide, South Australia. | lld:pubmed |
| pubmed-article:1715381 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1715381 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
